Combined P-glycoprotein and strong or moderate CYP3A4 inducers such as rifampicin may decrease exposure to<unk> , while combined P-glycoprotein and strong CYP3A4 inhibitors such as itraconazole may increase exposure to<unk> .<unk>  is an inhibitor of the breast cancer resistance protein (BCRP) transporter and can increase exposure to substrates for this protein such as rosuvastatin. It has been found to increase exposure to rosuvastatin by approximately 5-fold.
Darolutamide
Bicalutamide
Acetothiolutamide
Apalutamide
Nilutamide
Topilutamide
Flutamide
Salvestrol